Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Oct;32(5):e13878.
doi: 10.1111/jsr.13878. Epub 2023 Mar 19.

Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals

Rebecca Evans  1 , Haruhide Kimura  2 , Masato Nakashima  2 , Takashi Ishikawa  2 , Hiroshi Yukitake  2 , Motohisa Suzuki  2 , James Hazel  1 , Hélène Faessel  1 , Jingtao Wu  1 , Yaming Hang  1 , Robert Alexander  1 , Laura Rosen  1 , Deborah S Hartman  1 , Emiliangelo Ratti  1
Affiliations
Clinical Trial

Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals

Rebecca Evans et al. J Sleep Res. 2023 Oct.

Abstract

The orexin 2 receptor-selective agonist danavorexton (TAK-925) has been shown to produce wake-promoting effects in wild-type mice, narcolepsy-model mice, and individuals with narcolepsy type 1 and type 2. Here, we report wake-promoting effects of danavorexton in non-human primates and healthy men during their sleep phase. Electroencephalogram analyses revealed that subcutaneous administration of danavorexton significantly increased wakefulness in common marmosets (p < 0.05 at 0.1 mg kg-1 , and p < 0.001 at 1 mg kg-1 and 10 mg kg-1 ) and cynomolgus monkeys (p ≤ 0.05 at 1 mg kg-1 and 3 mg kg-1 ). In a phase 1b crossover, randomized, double-blind, placebo-controlled and active-controlled study in sleep-deprived healthy participants (ClinicalTrials.gov identifier: NCT03522506), modafinil 300 mg (used to demonstrate assay sensitivity) and continuous infusion of danavorexton 44 mg and danavorexton 112 mg showed statistically superior wake-promoting effects to placebo (n = 18). Measured using the Maintenance of Wakefulness Test, mean (standard deviation) sleep latencies during infusion of danavorexton 44 mg, danavorexton 112 mg and placebo were 21.4 (8.9), 31.8 (3.2) and 9.2 (6.4) min, respectively. Least-squares mean difference from placebo in average sleep latency was 16.8 min with danavorexton 44 mg and 30.2 min with danavorexton 112 mg (both p < 0.001). Karolinska Sleepiness Scale scores were statistically significantly lower (indicating decreased sleepiness) for participants receiving danavorexton than for those receiving placebo during infusion (danavorexton 44 mg, p = 0.010; danavorexton 112 mg, p < 0.001). Together, these results indicate that an orexin 2 receptor agonist increases wakefulness in non-human primates and healthy individuals during their sleep phase.

Keywords: excessive daytime sleepiness; hypocretins; novel medicine; sleep regulation; sleep/wake transition.

PubMed Disclaimer

References

REFERENCES

    1. Crofts, H. S., Wilson, S., Muggleton, N. G., Nutt, D. J., Scott, E. A., & Pearce, P. C. (2001). Investigation of the sleep electrocorticogram of the common marmoset (Callithrix jacchus) using radiotelemetry. Clinical Neurophysiology, 112(12), 2265-2273. https://doi.org/10.1016/s1388-2457(01)00699-x
    1. de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L., Gautvik, V. T., Bartlett, F. S., 2nd, Frankel, W. N., van den Pol, A. N., Bloom, F. E., Gautvik, K. M., & Sutcliffe, J. G. (1998). The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America, 95(1), 322-327. https://doi.org/10.1073/pnas.95.1.322
    1. Estabrooke, I. V., McCarthy, M. T., Ko, E., Chou, T. C., Chemelli, R. M., Yanagisawa, M., Saper, C. B., & Scammell, T. E. (2001). Fos expression in orexin neurons varies with behavioral state. The Journal of Neuroscience, 21(5), 1656-1662. https://doi.org/10.1523/jneurosci.21-05-01656.2001
    1. Evans, R., Kimura, H., Alexander, R., Davies, C. H., Faessel, H., Hartman, D. S., Ishikawa, T., Ratti, E., Shimizu, K., Suzuki, M., Tanaka, S., Yukitake, H., Dauvilliers, Y., & Mignot, E. (2022). Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proceedings of the National Academy of Sciences of the United States of America, 119(35), e2207531119. https://doi.org/10.1073/pnas.2207531119
    1. Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., & Nishino, S. (2003). Effects of IV and ICV hypocretin-1 (orexin a) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep, 26(8), 953-959. https://doi.org/10.1093/sleep/26.8.953

Publication types

Associated data

LinkOut - more resources